Is 'research' retatrutide or semaglutide the same as the real drug?

The real drugs: what they are and where they stand

Semaglutide and tirzepatide are approved prescription medicines. The FDA approved Ozempic (semaglutide) for type 2 diabetes in December 2017 and Wegovy (semaglutide) for chronic weight management in June 2021. It approved Mounjaro (tirzepatide) for type 2 diabetes in May 2022 and Zepbound (tirzepatide) for chronic weight management in November 2023. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors.

Their approvals rest on large randomized trials. In STEP 1, 1,961 adults with overweight or obesity and no diabetes received semaglutide or placebo for 68 weeks alongside lifestyle support. The semaglutide group lost substantially more weight, and nausea and diarrhea were the most common side effects. In SURMOUNT-1, 2,539 adults with obesity or overweight and no diabetes received tirzepatide or placebo for 72 weeks. Tirzepatide produced substantial and sustained weight loss, and its most common side effects were gastrointestinal, mostly mild to moderate.

Retatrutide is different: it is not an approved medicine anywhere in the US. It acts on three receptors (GIP, GLP-1 and glucagon). Two phase 3 trials reported results in 2026. TRIUMPH-1 randomized 2,339 adults with obesity and no diabetes to retatrutide or placebo for 80 weeks. Weight fell significantly more with retatrutide, and knee-arthritis pain and sleep-apnea events also improved in the relevant subgroups. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes and also found greater weight loss than with placebo. Gastrointestinal side effects were more common with retatrutide, and low blood pressure and dysesthesia (abnormal or unpleasant sensations) were reported more often than with placebo. The FDA states that retatrutide is not a component of any FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

Sources: accessdata.fda.gov · accessdata.fda.gov · accessdata.fda.gov · fda.gov · PubMed 33567185 · PubMed 35658024 · PubMed 42814954 · PubMed 42810372 · clinicaltrials.gov · fda.gov

Why a 'research' vial is a different product

An approved drug is more than its molecule. The FDA reviews how it is made, what impurities it may contain, how stable it is, and what goes on its label, and it can inspect the factory. A vial sold online as 'for research purposes' or 'not for human consumption' has gone through none of these checks. The name on the label tells you what the seller says is inside. It does not show that the contents match the name, the strength or the purity of an approved medicine.

The FDA has said this directly. It has issued warning letters to companies that illegally sold unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled 'for research purposes' or 'not for human consumption'. The agency notes that these products were sold directly to consumers for human use, with dosing instructions, and it urges people not to buy them because their quality is unknown and they may be harmful. The FDA also warns that counterfeit Ozempic has been found in the US, and that counterfeits can contain the wrong ingredient, too much or too little active ingredient, none at all, or other harmful substances. The agency's public warning-letter database lists these letters.

The supply chain behind the ingredient is also a concern. The FDA created Import Alert 66-80 so that shipments of foreign GLP-1 active ingredients, including semaglutide and tirzepatide, can be detained at the border unless the maker is on a 'Green List' of manufacturers that appear to follow good manufacturing practice. The alert says that 21% of the 48 GLP-1 ingredient sites the FDA evaluated were found noncompliant or did not answer records requests in time. It also describes sites that registered as GLP-1 makers, offered ingredients for import and then deregistered within a short period.

Sources: fda.gov · fda.gov · accessdata.fda.gov

What happened when products were tested

Few published studies have chemically tested GLP-1 products bought outside the legal supply chain. In a 2024 study, Hungarian and US researchers made test purchases of semaglutide from illegal online pharmacies that sold it without a prescription. Three vials arrived, and the three Ozempic pens that were ordered never arrived. All three vials were judged probably substandard or falsified. They failed more than half of the packaging-quality checks, contained more semaglutide than the label stated, and had a measured purity of only about 8% to 14%, against the 99% claimed on the label. No living microbes were found, but bacterial endotoxin was detected in every sample.

Some products have contained a completely different drug. A 2026 case report from Italy describes a woman who went into a hypoglycaemic coma after injecting a product sold online as semaglutide (Ozempic). Toxicology testing showed that the vial contained insulin instead. A 2026 Dutch report describes two people without diabetes or obesity who injected semaglutide obtained without a prescription. Both arrived in a coma with severe low blood sugar, and the cause was synthetic insulin. A European pharmacovigilance study found 234 reports linked to potentially counterfeit semaglutide between 2018 and 2025. Most of the suspected reactions were classed as serious, and low blood sugar and 'drug ineffective' were reported more often than with genuine semaglutide.

For retatrutide, a 2026 Australian study examined the composition and labeling accuracy of products sold as retatrutide. PubMed does not include an abstract for it, so we have not summarized its findings here.

Sources: PubMed 39509151 · PubMed 41125326 · PubMed 42390457 · PubMed 42137313 · PubMed 42559975

What the coded names mean, and why a code proves nothing

Online sellers often avoid brand or generic names and use short codes instead. Buyers generally read them by counting receptors and taking the last letter as the drug: 'GLP1-S' for semaglutide, 'GLP2-T' for the two-receptor drug tirzepatide, and 'GLP3-R' or simply 'R' for the three-receptor drug retatrutide. Codes like these let a listing hint at a famous medicine without using its name.

A code is a marketing label, not evidence of identity. It is set by the seller, it is not regulated, and it says nothing about what is inside, how pure it is, how much there is or how it was made. The FDA's warning letters show that a 'research use only' label does not change the legal picture when products are in fact sold for people to use. Case reports also describe the problem doctors face. In a 2026 case report from a Swiss hospital, a patient had been injected with an 'unverified product reported to contain retatrutide'. No one could confirm what it actually contained. Only independent lab testing of a specific batch can show what that batch contains, and even then the result applies only to that batch.

Sources: fda.gov · fda.gov · PubMed 42843917 · PubMed 39509151

Reported harms

Most published harm data concern compounded GLP-1 drugs, which are made by pharmacies and are also not FDA-approved. They are not the same as research-labeled vials, which have even less oversight. By May 31, 2026, the FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and it says these numbers are likely underreported. The FDA has also warned about dosing errors with compounded semaglutide in multiple-dose vials. Some patients drew up too much, and some health professionals miscalculated when converting between units of measurement. Reported effects included nausea, vomiting, abdominal pain, fainting, dehydration, pancreatitis and gallstones, and some patients were hospitalized.

Published data point the same way. A regional poison control center reported three people who became ill after incorrect use of compounded semaglutide, two of whom had injected ten times the intended amount. Their nausea, vomiting and abdominal pain lasted for days. An analysis of the FDA Adverse Event Reporting System from 2018 to 2024 found that compounded GLP-1 products had higher reporting odds than approved products for several side effects, preparation errors, contamination, manufacturing problems and hospitalization. The authors note that this design cannot show cause and effect. In a 2026 US study, 20 adults were given vials and supplies and asked to prepare grey-market semaglutide using only online information. On average they completed 15 of 34 steps correctly, and they made errors that could lead to wrong doses, needle-stick injuries or infection.

Case reports on products sold as retatrutide are starting to appear. A 2026 case report from a hospital in Zurich describes a woman in her mid-20s who had five days of persistent nausea and vomiting after injections given in a wellness setting by a coach with no medical qualifications. The authors judged the link to be probable. A 2026 report from a hospital in Edinburgh describes a man with type 1 diabetes developed severe vomiting, high ketone levels and kidney injury shortly after injecting an online product marketed as retatrutide. Because a gut infection was also found, the authors could not establish that the product caused the illness.

Sources: fda.gov · fda.gov · PubMed 37392810 · PubMed 40285721 · PubMed 42541373 · PubMed 42843917 · PubMed 42669023

What we don't know

We do not know how often research-labeled GLP-1 vials are accurate, because there is little systematic testing in the published literature. The best-described test in PubMed covered only three vials of semaglutide, from illegal online pharmacies. The Australian study of products sold as retatrutide has no abstract in PubMed. Some products could happen to contain the right molecule at a reasonable purity, but without testing a buyer cannot tell which ones do.

We also do not know the full scale of harm. Adverse-event and poison-center reports depend on someone recognizing and reporting a problem. The FDA says compounded-drug reports are likely underreported, and case reports cannot show cause and effect or how common a problem is. For retatrutide itself, the trial results so far come from a drug made, stored and supplied under trial conditions. Those safety findings cannot be assumed to apply to an unverified product sold under the same name or a code.

Sources: PubMed 39509151 · PubMed 42559975 · PubMed 40285721 · PubMed 42669023 · PubMed 42814954 · fda.gov

Profiles

Retatrutide profile → · Semaglutide profile → · Tirzepatide profile →

References

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med · 2021 · PMID 33567185
2. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med · 2022 · PMID 35658024
3. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med · 2026 · PMID 42814954
4. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet · 2026 · PMID 42810372
5. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res · 2024 · PMID 39509151
6. Hypoglycaemic coma induced by a falsified semaglutide product: a case report. Eur J Hosp Pharm · 2026 · PMID 41125326
7. [Insulin intoxications caused by falsified semaglutide]. Ned Tijdschr Geneeskd · 2026 · PMID 42390457
8. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Front Pharmacol · 2026 · PMID 42137313
9. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia. Drug Alcohol Rev · 2026 · PMID 42559975
10. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep · 2026 · PMID 42843917
11. Administration errors of compounded semaglutide reported to a poison control center-Case series. J Am Pharm Assoc (2003) · 2023 · PMID 37392810
12. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf · 2026 · PMID 40285721
13. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription. Public Health Rep · 2026 · PMID 42541373
14. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus · 2026 · PMID 42669023

Other sources

• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637
• https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215256Orig1s000ltr.pdf
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
• https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
• https://clinicaltrials.gov/study/NCT05929066
• https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
• https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
• https://www.accessdata.fda.gov/cms_ia/importalert_1186.html
• https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

These are original summaries of published research, written with AI assistance and checked against the cited sources. They are not medical advice and have not been reviewed by a clinician. Every PubMed reference was checked against PubMed's record for title, year and journal. All claim checks · Editorial standards